|
1
|
Yu F, Du L, Ojcius DM, Pan C and Jiang S:
Measures for diagnosing and treating infections by a novel
coronavirus responsible for a pneumonia outbreak originating in
Wuhan, China. Microbes Infect. 22:74–79. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chan KH, Chan JF, Tse H, Chen H, Lau CC,
Cai JP, Tsang AK, Xiao X, To KK, Lau SK, et al: Cross-reactive
antibodies in convalescent SARS patients' sera against the emerging
novel human coronavirus EMC (2012) by both immunofluorescent and
neutralizing antibody tests. J Infect. 67:130–140. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Perlman S: Another decade, another
coronavirus. N Engl J Med. 382:760–762. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
General Office of National Health
Committee. Office of State Administration of Traditional Chinese
Medicine. Notice on the issuance of a programme for the diagnosis
and treatment of novel coronavirus (2019-nCoV) infected pneumonia
(Trial Version 4).; 2020. Available from: http://bgs.satcm.gov.cn/.
|
|
5
|
Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P,
Wang X, Hu C, Ping R, Hu P, et al: Clinical features of 85 fatal
cases of COVID-19 from Wuhan. A retrospective observational study.
Am J Respir Crit Care Med. 201:1372–1379. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wang Z, Yang B, Li Q, Wen L and Zhang R:
Clinical features of 69 cases with coronavirus disease 2019 in
Wuhan, China. Clin Infect Dis. 71:769–777. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Li YK, Peng S, Li LQ, Wang Q, Ping W,
Zhang N and Fu XN: Clinical and transmission characteristics of
Covid-19-A retrospective study of 25 cases from a single thoracic
surgery department. Curr Med Sci. 40:295–300. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wang Z, Deng H, Ou C, Liang J, Wang Y,
Jiang M and Li S: Clinical symptoms, comorbidities and
complications in severe and non-severe patients with COVID-19: A
systematic review and meta-analysis without cases duplication.
Medicine (Baltimore). 99(e23327)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jazieh AR, Alenazi TH, Alhejazi A, Al Safi
F and Al Olayan A: Outcome of oncology patients infected with
coronavirus. JCO Glob Oncol. 6:471–475. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ye Z, Hong Y, Wu X, Hong D, Zhang Y, Dong
X, Rao Y and Lu X: Management of a colon cancer patient complicated
with COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban. 49:245–248.
2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
11
|
Charlson ME, Pompei P, Ales KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: Development and validation. J Chronic Dis.
40:373–383. 1987.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Charlson ME, Charlson RE, Peterson JC,
Marinopoulos SS, Briggs WM and Hollenberg JP: The Charlson
comorbidity index is adapted to predict costs of chronic disease in
primary care patients. J Clin Epidemiol. 61:1234–1240.
2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hall WH, Ramachandran R, Narayan S, Jani
AB and Vijayakumar S: An electronic application for rapidly
calculating Charlson comorbidity score. BMC Cancer.
4(94)2004.PubMed/NCBI View Article : Google Scholar
|
|
14
|
de Groot V, Beckerman H, Lankhorst GJ and
Bouter LM: How to measure comorbidity. a critical review of
available methods. J Clin Epidemiol. 56:221–229. 2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Charlson Comorbidity Index (CCI).
Available from: https://www.mdcalc.com/charlson-comorbidity-index-cci.
|
|
16
|
VAN Halteren HK and Vreugdenhil G: Age
adjusted charlson comorbidity index strongly influences survival,
irrespective of performance status and age, in patients with
advanced prostatic cancer treated with enzalutamide. Anticancer
Res. 39:863–866. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhao L, Leung LH, Wang J, Li H, Che J, Liu
L, Yao X and Cao B: Association between Charlson comorbidity index
score and outcome in patients with stage IIIB-IV non-small cell
lung cancer. BMC Pulm Med. 17(112)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Perri F, Muto P, Aversa C, Daponte A,
Della Vittoria G, Pepe S and Caponigro F: Integrated therapeutic
approaches in head and neck cancer: The importance of
multidisciplinary team management. Anticancer Agents Med Chem.
13:834–843. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chen MF, Tsai MS, Chen WC and Chen PT:
Predictive value of the pretreatment neutrophil-to-lymphocyte ratio
in head and neck squamous cell carcinoma. J Clin Med.
7(294)2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Valero C, Pardo L, López M, García J,
Camacho M, Quer M and León X: Pretreatment count of peripheral
neutrophils, monocytes, and lymphocytes as independent prognostic
factor in patients with head and neck cancer. Head Neck.
39:219–226. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Rassouli A, Saliba J, Castano R, Hier M
and Zeitouni AG: Systemic inflammatory markers as independent
prognosticators of head and neck squamous cell carcinoma. Head
Neck. 37:103–110. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wong BY, Stafford ND, Green VL and
Greenman J: Prognostic value of the neutrophil-to-lymphocyte ratio
in patients with laryngeal squamous cell carcinoma. Head Neck. 38
(Suppl 1):E1903–E1908. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Tsai MS, Chen WC, Lu CH and Chen MF: The
prognosis of head and neck squamous cell carcinoma related to
immunosuppressive tumor microenvironment regulated by IL-6
signaling. Oral Oncol. 91:47–55. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Setrerrahmane S and Xu H: Tumor-related
interleukins: Old validated targets for new anti-cancer drug
development. Mol Cancer. 16(153)2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bharti R, Dey G and Mandal M: Cancer
development, chemoresistance, epithelial to mesenchymal transition
and stem cells: A snapshot of IL-6 mediated involvement. Cancer
Lett. 375:51–61. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Banks WA, Kastin AJ and Gutierrez EG:
Penetration of interleukin-6 across the murine blood-brain barrier.
Neurosci Lett. 179:53–56. 1994.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Heinrich PC, Behrmann I, Müller-Newen G,
Schaper F and Graeve L: Interleukin-6-type cytokine signalling
through the gp130/Jak/STAT pathway. Biochem J. 334:297–314.
1998.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lauta VM: A review of the cytokine network
in multiple myeloma: Diagnostic, prognostic, and therapeutic
implications. Cancer. 97:2440–2452. 2003.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Scheller J, Ohnesorge N and Rose-John S:
Interleukin-6 trans-signalling in chronic inflammation and cancer.
Scand J Immunol. 63:321–329. 2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yu GT, Bu LL, Huang CF, Zhang WF, Chen WJ,
Gutkind JS, Kulkarni AB and Sun ZJ: PD-1 blockade attenuates
immunosuppressive myeloid cells due to inhibition of CD47/SIRPα
axis in HPV negative head and neck squamous cell carcinoma.
Oncotarget. 6:42067–42080. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kitamura H, Ohno Y, Toyoshima Y, Ohtake J,
Homma S, Kawamura H, Takahashi N and Taketomi A:
Interleukin-6/STAT3 signaling as a promising target to improve the
efficacy of cancer immunotherapy. Cancer Sci. 108:1947–1952.
2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sanders JM, Monogue ML, Jodlowski TZ and
Cutrell JB: Pharmacologic treatments for coronavirus disease 2019
(COVID-19): A review. JAMA. 323:1824–1836. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nitulescu GM, Paunescu H, Moschos SA,
Petrakis D, Nitulescu G, Ion GND, Spandidos DA, Nikolouzakis TK,
Drakoulis N and Tsatsakis A: Comprehensive analysis of drugs to
treat SARS-CoV-2 infection: Mechanistic insights into current
COVID-19 therapies (Review). Int J Mol Med. 46:467–488.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
He L, Ding Y, Zhang Q, Che X, He Y, Shen
H, Wang H, Li Z, Zhao L, Geng J, et al: Expression of elevated
levels of pro-inflammatory cytokines in SARS-CoV-infected
ACE2+ cells in SARS patients: Relation to the acute lung
injury and pathogenesis of SARS. J Pathol. 210:288–297.
2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Tang BS, Chan KH, Cheng VC, Woo PC, Lau
SK, Lam CC, Chan TL, Wu AK, Hung IF, Leung SY and Yuen KY:
Comparative host gene transcription by microarray analysis early
after infection of the Huh7 cell line by severe acute respiratory
syndrome coronavirus and human coronavirus 229E. J Virol.
79:6180–6193. 2005.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Nieto-Torres JL, DeDiego ML,
Verdiá-Báguena C, Jimenez-Guardeño JM, Regla-Nava JA,
Fernandez-Delgado R, Castaño-Rodriguez C, Alcaraz A, Torres J,
Aguilella VM and Enjuanes L: Severe acute respiratory syndrome
coronavirus envelope protein ion channel activity promotes virus
fitness and pathogenesis. PLoS Pathog. 10(e1004077)2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
DeDiego ML, Nieto-Torres JL, Regla-Nava
JA, Jimenez-Guardeño JM, Fernandez-Delgado R, Fett C,
Castaño-Rodriguez C, Perlman S and Enjuanes L: Inhibition of
NF-κB-mediated inflammation in severe acute respiratory syndrome
coronavirus-infected mice increases survival. J Virol. 88:913–924.
2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gordon SG and Mielicki WP: Cancer
procoagulant: A factor X activator, tumor marker and growth factor
from malignant tissue. Blood Coagul Fibrinolysis. 8:73–86.
1997.PubMed/NCBI
|
|
39
|
Cui S, Chen S, Li X, Liu S and Wang F:
Prevalence of venous thromboembolism in patients with severe novel
coronavirus pneumonia. J Thromb Haemost. 18:1421–1424.
2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang J, Hajizadeh N, Moore EE, McIntyre
RC, Moore PK, Veress LA, Yaffe MB, Moore HB and Barrett CD: Tissue
plasminogen activator (tPA) treatment for COVID-19 associated acute
respiratory distress syndrome (ARDS): A case series. J Thromb
Haemost. 18:1752–1755. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zhang Y, Xiao M, Zhang S, Xia P, Cao W,
Jiang W, Chen H, Ding X, Zhao H, Zhang H, et al: Coagulopathy and
antiphospholipid antibodies in patients with Covid-19. N Engl J
Med. 382(e38)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Fazel A, Quabius ES, Fabian A, Schleicher
T, Kress K, Laudien M, Huber K, Herzog A, Gonzales Donate M and
Hoffmann M: The influence of smoking and co-morbidity on dose
achievement in primary or adjuvant radio(Chemo)therapy in head and
neck squamous cell carcinoma (HNSCC). Front Oncol.
10(398)2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Cai G: Bulk and single-cell
transcriptomics identify tobacco-use disparity in lung gene
expression of ACE2, the receptor of 2019-nCov. Feb 17, 2020.
Available from: https://www.medrxiv.org/content/medrxiv/early/2020/02/17/2020.02.05.20020107.full.pdf.
|
|
44
|
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He
JX, Liu L, Shan H, Lei CL, Hui DSC, et al: Clinical characteristics
of coronavirus disease 2019 in China. N Engl J Med. 382:1708–1720.
2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Jordan SC, Zakowski P, Tran HP, Smith EA,
Gaultier C, Marks G, Zabner R, Lowenstein H, Oft J, Bluen B, et al:
Compassionate use of tocilizumab for treatment of SARS-CoV-2
pneumonia. Clin Infect Dis. 71:3168–3173. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Green DR: SARS-CoV2 vaccines: Slow is
fast. Sci Adv. 6(eabc7428)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Bartoli A, Gabrielli F, Alicandro T,
Nascimbeni F and Andreone P: COVID-19 treatment options: A
difficult journey between failed attempts and experimental drugs.
Intern Emerg Med 1-28, Jan 4, 2021 (Epub ahead of print).
|
|
48
|
Stratton CW, Tang YW and Lu H:
Pathogenesis-directed therapy of 2019 novel coronavirus disease. J
Med Virol. 93:1320–1342. 2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Hussain A, Hasan A, Nejadi Babadaei MM,
Bloukh SH, Chowdhury MEH, Sharifi M, Haghighat S and Falahati M:
Targeting SARS-CoV2 spike protein receptor binding domain by
therapeutic antibodies. Biomed Pharmacother.
130(110559)2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Grünewaldt A, Stützle S, Lehn A and Rohde
G: Dyspnoea and comorbidity in lung cancer-patients: The therapy
starts with taking the patients history. Pneumologie: Feb 17, 2021
(Epub ahead of print) (In German).
|
|
51
|
Media AS, Persson M, Tajhizi N and
Weinreich UM: Chronic obstructive pulmonary disease and
comorbidities' influence on mortality in non-small cell lung cancer
patients. Acta Oncol. 58:1102–1106. 2019.PubMed/NCBI View Article : Google Scholar
|
